Investigational drug · Phase 3
delpacibart braxlosiran
Also called: AOC-1020, del-brax
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for FSHD, FSHD1, FSHD2.
Phase 3Last checked: Nov 20, 2026Latest source record: Jul 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
2
Any phase or sponsor naming "delpacibart braxlosiran"
First trial start
2023
Apr 4, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "delpacibart braxlosiran", any sponsor or status.
Conditions studied
As listed on its trial records.
- FSHD
- FSHD1
- FSHD2
- Fascioscapulohumeral Muscular Dystrophy
- Fascioscapulohumeral Muscular Dystrophy Type 1
- Fascioscapulohumeral Muscular Dystrophy Type 2
- Facioscapulohumeral Muscular Dystrophy 1
- Facio-Scapulo-Humeral Dystrophy
- Facioscapulohumeral Muscular Dystrophy 2
- FSH Muscular Dystrophy
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "delpacibart braxlosiran" as an intervention, largest first.
- A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHDPivotal-lookingRecruiting
Avidity Biosciences, Inc.Industry
NCT07038200 · 200 participants (planned) · Start Jun 10, 2025 · Primary completion May 2028
Drug: AOC-1020; Placebo · For: Facioscapulohumeral Muscular Dystrophy; FSHD; FSHD - Facioscapulohumeral Muscular Dystrophy and 14 more
Sites: Orange, California; Palo Alto, California; Denver, Colorado · 46 sites in all
- Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)Active, not recruiting
Avidity Biosciences, Inc.Industry
NCT06547216 · 84 participants (planned) · Start Jul 25, 2024 · Primary completion Apr 2030
Drug: AOC 1020 · For: FSHD; FSHD1; FSHD2 and 24 more
Sites: Los Angeles, California; Palo Alto, California; San Diego, California · 17 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Development of a DUX4-targeting antibody oligonucleotide conjugate as a therapy for FSHD.
Malecova B, Sala D, Melikian GM, et al. · Nucleic Acids Res 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.